MEFIB、MAST与FAST在NAFLD患者中检测2期及以上纤维化的头对头比较
这项前瞻性研究纳入563例经活检证实的NAFLD患者,比较MEFIB、MAST和FAST三种无创模型检测显著纤维化的诊断性能。MEFIB的AUC为0.901,优于MAST的0.770和FAST的0.725(均p<0.001);MEFIB的排除标准阴性预测值也显著更高。
要点
- MEFIB检测显著纤维化的AUC为0.901,优于MAST的0.770和FAST的0.725(均p<0.001)。
- MEFIB排除标准的阴性预测值为90.1%,显著高于MAST的69.6%和FAST的71.8%(均p<0.001)。
- MEFIB纳入标准覆盖34.1%的研究人群,高于MAST的26.6%(p=0.006)。
核心结论
- MEFIB检测显著纤维化及「高风险」NASH均优于MAST和FAST,三种模型均可用于NAFLD风险分层。
研究设计与样本
- 前瞻性研究,纳入563例经活检证实的NAFLD患者,来自南加州和日本的两个前瞻性队列,同期接受MRE、MRI-PDFF和FibroScan检查。
主要发现
- 队列平均年龄56.5岁,女性占51%,显著纤维化占51.2%。
- 检测显著纤维化:MEFIB的AUC为0.901(95%CI 0.875-0.928),MAST为0.770(95%CI 0.730-0.810),FAST为0.725(95%CI 0.683-0.767),MEFIB优于MAST和FAST(均p<0.001)。
- 纳入标准阳性预测值:MEFIB为95.3%,显著高于FAST的83.5%(p=0.001),数值上高于MAST的90.0%但未达统计学显著(p=0.056)。
- 纳入标准覆盖研究人群比例:MEFIB为34.1%,高于MAST的26.6%(p=0.006)。
- 排除标准阴性预测值:MEFIB为90.1%,显著高于MAST的69.6%和FAST的71.8%(均p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with non-alcoholic fatty liver disease (NAFLD) and significant fibrosis (fibrosis stage ≥2) are candidates for pharmacological trials. The aim of this study was to perform a head-to-head comparison of the diagnostic test characteristics of three non-invasive stiffness-based models including MEFIB (magnetic resonance elastography [MRE] plus FIB-4), MAST (magnetic resonance imaging [MRI]-aspartate aminotransferase [AST]), and FAST (FibroScan-AST) for detecting significant fibrosis. METHODS: This prospective study included 563 patients with biopsy-proven NAFLD undergoing contemporaneous MRE, MRI proton density fat fraction (MRI-PDFF) and FibroScan from two prospective cohorts derived from Southern California and Japan. Diagnostic performances of models were evaluated by area under the receiver-operating characteristic curve (AUC). RESULTS: The mean age of the cohort was 56.5 years (51% were women). Significant fibrosis was observed in 51.2%. To detect significant fibrosis, MEFIB outperformed both MAST and FAST (both p <0.001); AUCs for MEFIB, MAST, and FAST were 0.901 (95% CI 0.875-0.928), 0.770 (95% CI 0.730-0.810), and 0.725 (95% CI 0.683-0.767), respectively. Using rule-in criteria, the positive predictive value of MEFIB (95.3%) was significantly higher than that of FAST (83.5%, p = 0.001) and numerically but not statistically greater than that of MAST (90.0%, p = 0.056). Notably, MEFIB's rule-in criteria covered more of the study population than MAST (34.1% vs. 26.6%; p = 0.006). Using rule-out criteria, the negative predictive value of MEFIB (90.1%) was significantly higher than that of either MAST (69.6%) or FAST (71.8%) (both p <0.001). Furthermore, to diagnose "at risk" non-alcoholic steatohepatitis defined as NAFLD activity score ≥4 and fibrosis stage ≥2, MEFIB outperformed both MAST and FAST (both p <0.05); AUCs for MEFIB, MAST, and FAST were 0.768 (95% CI 0.728-0.808), 0.719 (95% CI 0.671-0.766), and 0.687 (95% CI 0.640-0.733), respectively. CONCLUSIONS: MEFIB was better than MAST and FAST for detection of significant fibrosis as well as "at risk" NASH. All three models provide utility for the risk stratification of NAFLD. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) affects over 25% of the general population worldwide and is one of the main causes of chronic liver disease. Because so many individuals have NAFLD, it is not practical to perform liver biopsies to identify those with more severe disease who may require pharmacological interventions. Therefore, accurate non-invasive tests are crucial. Herein, we compared three such tests and found that a test called MEFIB was the best at detecting patients who might require treatment.
引用
- Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol. 2022. PMID: 35973577. doi:10.1016/j.jhep.2022.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。